Trial Summary
What is the purpose of this trial?
Poor emotion recognition has been associated with poor quality of interpersonal relationships, loss of employment, behavioral problems, reduced social reintegration, social isolation and even suicide. Deficits in emotion recognition are common in traumatic brain injury (TBI) and in post-traumatic stress disorder (PTSD) but these deficits have not been well studied in Veterans with both mild TBI (mTBI) and PTSD. Currently there are no interventions for emotion recognition in Veterans with mTBI and PTSD, and interventions for severe TBI have lacked training of both facial and vocal emotion recognition. In a preliminary study of an innovative combination of facial and vocal modalities, a multimodal affect recognition training (MMART) showed promise but lacked attention training that is an essential component in recognizing emotions in our daily lives. Given the need to improve relationships and productivity in Veterans with mTBI and PTSD, a study is needed to determine the effectiveness of a MMART combined with attention training.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment Attention Training, Multimodal Affect Recognition Training (MMART) combined with Attention Training, Brain Health Workshop, Multimodal affect recognition training, Multimodal Affect Recognition Training (MMART), Facial and Vocal Emotion Recognition Training for TBI and PTSD?
Research shows that people with traumatic brain injury (TBI) often struggle to recognize emotions from facial and vocal cues, which can affect their social interactions. Studies suggest that training focused on recognizing facial emotions can help improve these skills, as seen in individuals with chronic TBI who showed improvements after such training.12345
Is the Emotion & Attention Training for TBI and PTSD safe for humans?
The research articles provided do not contain specific safety data for the Emotion & Attention Training or its related programs. However, these types of cognitive and emotional training programs are generally considered safe as they focus on improving cognitive functions and emotional recognition without invasive procedures.45678
How is the Emotion & Attention Training treatment for TBI and PTSD different from other treatments?
This treatment is unique because it combines attention training with multimodal affect recognition training, which focuses on improving the ability to recognize emotions from facial and vocal cues. Unlike other treatments, it specifically targets the social communication challenges faced by individuals with TBI and PTSD, which are often overlooked in traditional therapies.12345
Research Team
Julia K. Waid-Ebbs, PhD
Principal Investigator
North Florida/South Georgia Veterans Health System, Gainesville, FL
Eligibility Criteria
This trial is for Veterans who have mild traumatic brain injury (mTBI) and PTSD, can hear and see normally, speak English fluently, and struggle with recognizing emotions or paying attention. It's not for those with chronic diseases, schizophrenia, or bipolar disorder.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo MultiModal Affect Recognition Training (MMART) combined with attention training over 8 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Attention Training (Behavioural Intervention)
- Brain Health Workshop (Behavioural Intervention)
- Multimodal affect recognition training (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
VA Office of Research and Development
Lead Sponsor
Dr. Grant Huang
VA Office of Research and Development
Acting Chief Research and Development Officer
PhD in Medical Psychology and Master of Public Health from the Uniformed Services University of Health Sciences
Dr. Erica M. Scavella
VA Office of Research and Development
Chief Medical Officer since 2022
MD from University of Massachusetts School of Medicine